Erik Tambuyzer
Directeur/Membre du Conseil chez Augustine Therapeutics NV
Postes actifs de Erik Tambuyzer
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Augustine Therapeutics NV
 Augustine Therapeutics NV Medical/Nursing ServicesHealth Services Augustine Therapeutics NV is a Belgian company that focuses on developing innovative therapies for neuromuscular and neurodegenerative diseases. The company is based in Leuven, Belgium. The company's main focus is on HDAC6, a class II histone deacetylase, which is a well-known molecular target in various diseases, particularly neurodegenerative disorders and neuropathies. The company was founded in 2019, and Sylvain Celanire has been the CEO of the company since 2020. | Directeur/Membre du Conseil | 19/03/2021 | - |
Historique de carrière de Erik Tambuyzer
Formation de Erik Tambuyzer
| Katholieke Universiteit Leuven | Doctorate Degree |
Statistiques
Internationale
| Belgique | 3 |
Opérationnelle
| Director/Board Member | 1 |
| Doctorate Degree | 1 |
Sectorielle
| Health Services | 2 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Augustine Therapeutics NV
Augustine Therapeutics NV Medical/Nursing ServicesHealth Services Augustine Therapeutics NV is a Belgian company that focuses on developing innovative therapies for neuromuscular and neurodegenerative diseases. The company is based in Leuven, Belgium. The company's main focus is on HDAC6, a class II histone deacetylase, which is a well-known molecular target in various diseases, particularly neurodegenerative disorders and neuropathies. The company was founded in 2019, and Sylvain Celanire has been the CEO of the company since 2020. | Health Services |
- Bourse
- Insiders
- Erik Tambuyzer
- Expérience
